Peptide questions · Setmelanotide
Setmelanotide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for setmelanotide are skin darkening, injection site reactions and nausea, among 9 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The Imcivree label has no boxed warning.
What is commonly reported with setmelanotide
- Skin darkening
- Injection site reactions
- Nausea
- Headache
- Diarrhea
- Abdominal pain
- Vomiting
- Low mood
- Spontaneous erections
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Skin darkening | None: listed for Setmelanotide alone |
| Injection site reactions | None: listed for Setmelanotide alone |
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Headache | 3: Exenatide, Orforglipron, Pramlintide |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Abdominal pain | 7: Semaglutide (oral), Tirzepatide, Retatrutide, Dulaglutide and 3 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Low mood | None: listed for Setmelanotide alone |
| Spontaneous erections | None: listed for Setmelanotide alone |

Model. Individual results vary.
Which setmelanotide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Setmelanotide shares 5 of its 9 listed effects with at least one other metabolic & GLP-1 compound; skin darkening, injection site reactions, low mood and spontaneous erections are listed for setmelanotide alone.
What the setmelanotide safety notes say
The library’s safety note
The Imcivree label has no boxed warning. Its warnings: spontaneous erections in men and sexual side effects in women (an erection lasting more than 4 hours needs emergency care); depression and suicidal thoughts, as with some other drugs that act in the brain, so mood is watched and a history of depression raises the risk; serious allergic reactions, including anaphylaxis; skin darkening in most trial patients, reversible after stopping, plus darker or new moles, so the label calls for a full-body skin check before starting and during treatment; in hypothalamic obesity, acute adrenal insufficiency (serious in 5% vs 0% on placebo) and, with central diabetes insipidus, low or high sodium. It is not recommended in end-stage kidney disease or while breastfeeding. These are label findings; review them with your clinician.
The library’s interaction note
No clinical drug-interaction studies have been done; in lab tests setmelanotide showed a low potential for interactions through liver enzymes, transporters or protein binding (label). In hypothalamic obesity with diabetes insipidus, the label suggests watching sodium and adjusting the diabetes insipidus medicines as needed. It shares the melanocortin receptors with Melanotan II and PT-141. Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the setmelanotide reports come from
The library rates the evidence on setmelanotide as established: clinical trials or FDA-approved use exist.
Of the library’s 6 research notes on setmelanotide, 4 rest on randomized trials and 2 on clinical data.
Our 8 study pages on setmelanotide: 1 meta-analysis, 1 randomized trial and 6 clinical trials.
So setmelanotide has controlled trials in people to set its listed effects against.
What our setmelanotide study pages report on safety
Setmelanotide: injection-site reactions in 96% in pooled trials
Meta-analysis, human, 2026: Nausea occurred in 36%, vomiting in 26% and diarrhea in 21%. In the FDA database, the side effects reported more often than expected were skin hyperpigmentation, injection-site reactions, nausea, melanocytic nevus (moles) and ephelides (freckles), and the case reports matched these patterns.
Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesity
Randomized trial, human, 2026: Adverse events occurred in 100% of the setmelanotide group and 90% of the placebo group, and serious adverse events in 28% and 8%. The most common side effects on setmelanotide were skin darkening (hyperpigmentation), nausea, vomiting and headache.
Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)
Clinical trial, human, 2025: All side effects were mild or moderate, most often skin darkening, vomiting, colds, upper airway infections, and injection site reactions, and there were no serious side effects.
Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesity
Clinical trial, human, 2024: Common side effects were nausea (61%), vomiting (33%), skin darkening (33%) and diarrhea (22%). In a small, uncontrolled trial, setmelanotide lowered BMI and hunger in people whose obesity followed hypothalamic damage, and nausea and skin darkening were common.
Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weight
Clinical trial, human, 2020: Injection site reactions happened in everyone, hyperpigmentation (skin darkening) in all POMC participants, and nausea and vomiting were also seen. There were no serious treatment-related side effects in either trial.
Questions people ask
What are the side effects of setmelanotide?
The side effects most commonly reported for setmelanotide are skin darkening, injection site reactions and nausea, among 9 the library lists; the library’s evidence on it includes controlled trials in people.
Do setmelanotide’s side effects come from human studies?
The library rates the evidence on setmelanotide as established, and the library’s evidence on it includes controlled trials in people.
Which setmelanotide side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists skin darkening, injection site reactions, low mood and spontaneous erections for setmelanotide alone.
Does setmelanotide interact with other medicines?
The library’s interaction note on setmelanotide begins: No clinical drug-interaction studies have been done; in lab tests setmelanotide showed a low potential for interactions through liver enzymes, transporters or protein binding (label).